BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32424617)

  • 21. Genetics of pancreatic neuroendocrine tumors: implications for the clinic.
    Pea A; Hruban RH; Wood LD
    Expert Rev Gastroenterol Hepatol; 2015; 9(11):1407-19. PubMed ID: 26413978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression.
    Martin DR; LaBauve E; Pomo JM; Chiu VK; Hanson JA; Gullapalli RR
    Pancreas; 2018 Apr; 47(4):502-510. PubMed ID: 29521944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathologic research update of colorectal neuroendocrine tumors.
    Ni SJ; Sheng WQ; Du X
    World J Gastroenterol; 2010 Apr; 16(14):1713-9. PubMed ID: 20380002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.
    Tang LH; Untch BR; Reidy DL; O'Reilly E; Dhall D; Jih L; Basturk O; Allen PJ; Klimstra DS
    Clin Cancer Res; 2016 Feb; 22(4):1011-7. PubMed ID: 26482044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Whole genome sequencing reveals the independent clonal origin of multifocal ileal neuroendocrine tumors.
    Mäkinen N; Zhou M; Zhang Z; Kasai Y; Perez E; Kim GE; Thirlwell C; Nakakura E; Meyerson M
    Genome Med; 2022 Aug; 14(1):82. PubMed ID: 35922826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing.
    Li W; Qiu T; Guo L; Ying J
    Cancer Lett; 2017 Dec; 410():92-99. PubMed ID: 28942013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutation analysis of 13 driver genes of colorectal cancer-related pathways in Taiwanese patients.
    Chang YC; Chang JG; Liu TC; Lin CY; Yang SF; Ho CM; Chen WT; Chang YS
    World J Gastroenterol; 2016 Feb; 22(7):2314-25. PubMed ID: 26900293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular deciphering of primary liver neuroendocrine neoplasms confirms their distinct existence with foregut-like profile.
    de Mestier L; Nicolle R; Poté N; Rebours V; Cauchy F; Hentic O; Maire F; Ronot M; Lebtahi R; Sauvanet A; Paradis V; Ruszniewski P; Couvelard A; Cros J
    J Pathol; 2022 Sep; 258(1):58-68. PubMed ID: 35681273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR pathway subgroups in Chilean colorectal cancer patients, detected by mutational and expression profiles, associated to different clinicopathological features.
    Alvarez K; Orellana P; Villarroel C; Contreras L; Kawachi H; Kobayashi M; Wielandt AM; De la Fuente M; Triviño JC; Kronberg U; Carvallo P; López-Köstner F
    Tumour Biol; 2017 Sep; 39(9):1010428317724517. PubMed ID: 28936923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Independent somatic evolution underlies clustered neuroendocrine tumors in the human small intestine.
    Elias E; Ardalan A; Lindberg M; Reinsbach SE; Muth A; Nilsson O; Arvidsson Y; Larsson E
    Nat Commun; 2021 Nov; 12(1):6367. PubMed ID: 34737276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
    Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
    Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin.
    Lee DW; Han SW; Bae JM; Jang H; Han H; Kim H; Bang D; Jeong SY; Park KJ; Kang GH; Kim TY
    Clin Cancer Res; 2019 Oct; 25(20):6141-6147. PubMed ID: 31285374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets.
    van Riet J; van de Werken HJG; Cuppen E; Eskens FALM; Tesselaar M; van Veenendaal LM; Klümpen HJ; Dercksen MW; Valk GD; Lolkema MP; Sleijfer S; Mostert B
    Nat Commun; 2021 Jul; 12(1):4612. PubMed ID: 34326338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing.
    Wong HL; Yang KC; Shen Y; Zhao EY; Loree JM; Kennecke HF; Kalloger SE; Karasinska JM; Lim HJ; Mungall AJ; Feng X; Davies JM; Schrader K; Zhou C; Karsan A; Jones SJM; Laskin J; Marra MA; Schaeffer DF; Gorski SM; Renouf DJ
    Cold Spring Harb Mol Case Stud; 2018 Feb; 4(1):. PubMed ID: 29092957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular characterization of sessile serrated adenoma/polyps with dysplasia/carcinoma based on immunohistochemistry, next-generation sequencing, and microsatellite instability testing: a case series study.
    Murakami T; Akazawa Y; Yatagai N; Hiromoto T; Sasahara N; Saito T; Sakamoto N; Nagahara A; Yao T
    Diagn Pathol; 2018 Nov; 13(1):88. PubMed ID: 30458818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix.
    Xing D; Zheng G; Schoolmeester JK; Li Z; Pallavajjala A; Haley L; Conner MG; Vang R; Hung CF; Wu TC; Ronnett BM
    Am J Surg Pathol; 2018 Jun; 42(6):750-760. PubMed ID: 29505425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine.
    Simbolo M; Vicentini C; Mafficini A; Fassan M; Pedron S; Corbo V; Mastracci L; Rusev B; Pedrazzani C; Landoni L; Grillo F; Cingarlini S; Rindi G; Luchini C; Scarpa A; Lawlor RT
    Virchows Arch; 2018 Dec; 473(6):709-717. PubMed ID: 30219970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.
    Klempner SJ; Gershenhorn B; Tran P; Lee TK; Erlander MG; Gowen K; Schrock AB; Morosini D; Ross JS; Miller VA; Stephens PJ; Ou SH; Ali SM
    Cancer Discov; 2016 Jun; 6(6):594-600. PubMed ID: 27048246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinicopathological significance of angiogenesis in hindgut neuroendocrine tumors obtained via an endoscopic procedure.
    Okubo Y; Motohashi O; Nakayama N; Nishimura K; Kasajima R; Miyagi Y; Shiozawa M; Yoshioka E; Suzuki M; Washimi K; Kawachi K; Nito M; Kameda Y; Yokose T
    Diagn Pathol; 2016 Nov; 11(1):128. PubMed ID: 27821179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group.
    Vollbrecht C; Werner R; Walter RF; Christoph DC; Heukamp LC; Peifer M; Hirsch B; Burbat L; Mairinger T; Schmid KW; Wohlschlaeger J; Mairinger FD
    Br J Cancer; 2015 Dec; 113(12):1704-11. PubMed ID: 26645239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.